Company reduces expected 2026 cash burn to approximately $19 million while maintaining development timeline and targeting system design freeze by year-end 2026

Vicarious Surgical Inc. (OTCID: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery, today announced a series of strategic actions intended to strengthen the Company’s financial position, enhance trading liquidity, and support a potential relisting of its common stock on a national exchange.

Over the past several months, Vicarious Surgical has implemented significant operational and cost discipline initiatives designed to align the Company’s expense structure with its current stage of development while maintaining progress toward key technology milestones.

As a result of these initiatives, the Company expects full-year 2026 cash burn of approximately $19 million, a substantial reduction from the approximately $35 million burn guidance provided in late 2025. In mid-2025, the Company’s annual cash burn was approximately $50 million due to its operating structure. These changes reflect a significant structural improvement in the Company’s cost profile, including increased use of outsourcing and operational efficiencies, while preserving progress toward key development milestones.

The Company’s strategic cost discipline has not slowed momentum in the development of the Vicarious Surgical System. Vicarious Surgical remains on track to achieve system design freeze by the end of 2026, a critical milestone in the Company’s regulatory and commercialization roadmap.

Based on its current operating plan, the Company believes that its existing cash resources provide runway through the second quarter of 2026, allowing the Company to pursue its capital markets strategy.

Capital Markets Strategy

As part of its broader strategy to strengthen the Company’s capital markets profile, Vicarious Surgical has submitted an application to list its Class A common stock on the Nasdaq Capital Market.

In connection with this initiative, the Company has filed a preliminary proxy statement with the Securities and Exchange Commission seeking stockholder approval to authorize the Company’s Board of Directors to implement a reverse stock split of the Company’s common stock at a ratio to be determined by the Board. The reverse stock split is intended to enable the Company’s shares to meet Nasdaq’s minimum bid price requirement for listing.

Vicarious Surgical is exploring capital raising strategies to support continued development of the Vicarious Surgical System and assist the Company in satisfying applicable Nasdaq initial listing requirements.

There can be no assurance that the Company will be able to satisfy Nasdaq’s listing standards or complete any proposed capital raising alternative.

OTCQB Application and Trading Liquidity

Following the Company’s recent transition from the New York Stock Exchange, its common stock began trading on the OTCID market tier. The Company has submitted an application to upgrade its quotation to the OTCQB Venture Market, which is designed for early-stage and developing companies.

The Company believes that trading on the OTCQB Venture Market would improve market visibility and facilitate greater market maker participation, which may enhance trading liquidity while the Company pursues its potential relisting on a national exchange.

Management Commentary

“Over the past several months, we have taken decisive steps to streamline our operating structure and significantly reduce our cash burn while maintaining our core development timeline,” said Stephen From, Chief Executive Officer of Vicarious Surgical.

“These actions position us with a more capital-efficient operating model while we continue advancing toward system design freeze by year-end. At the same time, we are actively pursuing a path back to a national exchange through our Nasdaq listing application. We believe these steps strengthen our foundation and support our long-term objective of bringing our robotic surgical platform to market.”

About Vicarious Surgical

Founded in 2014, Vicarious Surgical is a next-generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and has received backing by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.

In accordance with guidance provided by the SEC regarding use by a company of its websites and social media channels as a means to disclose material information to investors and to comply with its disclosure obligations under Regulation FD, the Company hereby notifies investors, the media and other interested parties that it intends to continue to use its investor relations website (https://investor.vicarioussurgical.com/), its LinkedIn page (https://linkedin.com/company/vicarious-surgical/) and its X feed (@VicariousSurg) to publish important information about the Company, including information that may be deemed material to investors. The list of social media channels that the Company uses may be updated on its investor relations website from time to time. The Company encourages investors, the media, and other interested parties to review the information the Company posts on its website and social media channels as described above, in addition to information announced by the Company through its SEC filings, press releases and public conference calls and webcasts.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding expected full year 2026 cash burn and its impact on development momentum, the timeline for design freeze for the Vicarious Surgical System, the Company’s intention to list its Class A common stock on the Nasdaq Capital Market, the Company’s ability to conduct a reverse stock split and the ability for the reverse stock split to allow the Class A common stock to meet the bid price requirement for listing on the Nasdaq Capital Market, the ability to transfer the quotation of the Company’s Class A common stock to the OTCQB Venture Market, the potential to pursue capital raising strategies to meet initial listing standards for the Nasdaq Capital Market, and the anticipated benefits of quotation on the OTCQB Venture Market, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the Company’s ability to obtain and maintain listing on a national securities exchange; the impacts of the Company’s reduced cash burn; the price of the Class A common stock following any reverse stock split; the Company’s future business strategy; the approval, commercialization and adoption of the Company’s initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s product candidates and services; the Company’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company’s business, financial condition and results of operations; the Company’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company’s filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260316676583/en/